Fusion Pharmaceuticals (FUSN)
FUSN
Oncology
BiotechSign Signal Grade
F
Signal Grade
24.4/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
38
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
3
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
3 Phase 2
Trial Phase Breakdown
2
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. — Cancer 2026 Oct 1 PMID 42829896
- Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy. — JCO Precis Oncol 2026 Oct PMID 42826365
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Fusion Pharmaceuticals.
Full FUSN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.